Canopy Growth Q2 Net Loss Widens to C$40.7M; Material Weakness Persists
CGC is trading near its 52-week low of $0.641 (9.2% above the low).
Summary
Canopy Growth's Q2 FY2027 net loss widened to C$40.7M from C$5.0M, mostly on non-cash fair value swings in its Canopy USA holdings, while revenue grew 22% to C$81.4M. The previously disclosed material weakness in internal controls remains unremediated.
Key Events · Earnings and Guidance · CGC
-
Net Loss Widens on Non-Cash Marks
Q2 FY2027 net loss was C$40.7M versus C$5.0M a year earlier, driven by a C$35.8M swing in fair value changes on Canopy USA related assets (C$11.9M expense vs. C$23.9M income).
-
Revenue Up 22% to C$81.4M
Net revenue rose to C$81.4M from C$66.7M, with international cannabis up 141% to C$12.3M; Adjusted EBITDA loss narrowed to C$2.9M from C$3.0M.
-
Material Weakness Still Unremediated
The equity-versus-liability classification weakness in USD-denominated warrants persists, and disclosure controls were concluded not effective as of September 30, 2026.
-
Cash Falls C$117.3M in Six Months
Cash and equivalents ended at C$247.3M versus C$364.7M at March 31, 2026, with C$37.6M used in operations and C$71.7M moved into short-term investments.
Analysis · CGC · Life Sciences
The headline loss ballooned to C$40.7M from C$5.0M a year ago, but the swing is almost entirely non-cash: a C$35.8M year-over-year reversal in fair value marks on the Canopy USA assets (a C$11.9M expense this quarter versus a C$23.9M gain a year ago, driven by the TerrAscend share price). Revenue growth of 22% to C$81.4M and a slightly narrower Adjusted EBITDA loss of C$2.9M show the core cannabis business improving. Against that, the company still carries an unremediated material weakness in internal controls over equity-versus-liability classification of USD-denominated warrants, and its disclosure controls were concluded not effective at September 30, 2026 — a governance overhang on top of a C$247.3M cash balance that fell by C$117.3M in six months. Acreage remains in default on its credit agreement, with forbearance now running to January 31, 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CGC was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $301.2M. The 52-week trading range was $0.64 to $2.38. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.